PYPD - PolyPid GAAP EPS of -$0.32 beats by $0.07
- PolyPid press release ( NASDAQ: PYPD ): Q4 GAAP EPS of -$0.32 beats by $0.07 .
- As of December 31, 2022, the company had cash and cash equivalents and deposits in the amount of $12.6M, compared to $32.2M at December 31, 2021.
- PolyPid expects that this cash balance will be sufficient to fund operations well into the third quarter of this year .
- Company expects to resume patient recruitment in Q2 2023 into Ongoing SHIELD II Trial, which will be enriched with ~550 additional patients to complete clinical testing for Potential NDA.
- Top-line Results from SHIELD II Trial Anticipated mid-2024.
For further details see:
PolyPid GAAP EPS of -$0.32 beats by $0.07